

Kevin C. Clayton

Partner

Washington, D.C.

Biography

Kevin Clayton is a practical and experienced adviser who brings a collaborative and cost-effective approach to corporate and commercial matters. He regularly advises clients on mergers and acquisitions, equity and debt financings, joint ventures and complex contracting and corporate governance matters, particularly focusing on representation of funds, corporate investors, and emerging companies from start-up through unicorn in financing, commercial, and acquisition transactions.

In addition to his two decades of advising on mergers and acquisitions and financing transactions, Kevin also has years of experience managing a wide array of commercial matters and complex contracting arrangements, such as joint venture, license, supply, distribution, collaboration, manufacturing, service, employment, and consulting agreements.

While Kevin often represents emerging and growth-stage companies on formation, financing, commercial, and acquisition matters, he also advises later-stage and public companies, particularly with respect to investment, acquisition, joint venture and licensing transactions.

Kevin represents clients in various industry sectors, but has particular experience with matters in the life sciences and technology sectors.

Additionally, Kevin is currently a lecturer on corporate transactions at the University of Virginia School of Law.



Phone

+1 202 637 5489

Fax

+1 202 637 5910

Email

kevin.clayton@hoganlovells.com

Practices

Venture Capital and Emerging Companies

Mergers and Acquisitions

Private Equity

Joint Ventures

Commercial

Complex Contracting

Intellectual Property

Trade Secrets and Confidential Know-how

Privacy and Cybersecurity

Investment Funds

Space and Satellite

Uncrewed Aircraft Systems

Representative experience

Advising Ford Motor Company on Volkswagen AG's US\$2.6bn investment into Ford's autonomous vehicle platform company, Argo AI.

Represented New Enterprise Associates in multiple venture capital investments.

Represented Gilead Sciences and Kite Pharma in multiple venture investments.

Represented Daimler AG in its investment in Via Transportation, Inc.

Represented OptiNose, Inc. in its US\$37m Series D financing, prior equity and debt financings, and general corporate matters.

Represented a publicly traded biotechnology company in several acquisitions and divestitures and numerous strategic venture investments.

Represented Fred Hutchinson Cancer Research Center in Juno Therapeutics, Inc.'s formation and US\$176m Series A financing, US\$134m Series B financing, and related matters.

Represented PhishMe, Inc. in its US\$42m Series C financing, prior equity and debt financings, general corporate matters, and its transaction with Malcovery Security, LLC.

Represented RTW Investments on venture investments in Monte Rosa Therapeutics' US\$95m Series C financing, Acelyrin's US\$250m Series B financing and InBrace's US\$102m Series D financing.

Represented Dental Care Alliance, LLC in its 2015 sale to Harvest Partners, LP.

Represented Avidea Technologies in its acquisition by Vaccitech PLC.

Represented Paladin Capital on multiple venture investments.

Represented New York University in connection with Spin Transfer Technologies, Inc.'s US\$70m financing and other similar transactions.

Industries

Life Sciences and Health Care

Automotive

Mobility and Transportation

Technology and Telecoms

Private Capital

Education

Areas of focus

Emerging Companies

Private Equity and Venture Capital Funds

Company Formation

Exits

Carve-outs, Spin-offs, and Split-offs

Cross-border Mergers and Acquisitions

Corporate Group Structures

IP Rights in Transactions

Technology Contracts

IP Licensing, Commercialization, and Technology Transfer

Agency and Distribution

Manufacturing

Corporate and Commercial Transactions

Emerging Companies and Investors - Life Sciences and Health Care

Automotive Venture Capital Investors

Consumer Venture Capital Investors

FinTech

Financial Venture Capital Investors

Represented a luxury vacation club in a variety of equity financings, mortgage-backed debt financings, and acquisitions.

Latest thinking and events

- Press Releases
 - Hogan Lovells advises Avidia Technologies on acquisition by Vaccitech
- Press Releases
 - Hogan Lovells represents Gilead Sciences in strategic oncology collaboration with Tango Therapeutics

FinTech Venture Capital

Life Sciences and Health Care
Venture Capital Investors

Strategic / Corporate Venture
Capital Investors

Technology Venture Capital
Investors

Raising Equity Capital

Connected Cars

Cell, Tissue, and Gene Therapies

Hospitals and Health Care Providers

Medical Devices

Pharmaceuticals and Biotechnology

Hotels and Leisure

Education and admissions

Education

J.D., University of Virginia School of
Law, 1998

B.A., University of Virginia, 1992

Bar admissions and qualifications

District of Columbia

Virginia
